iodomethylcholine

Iodomethylcholine (IMC) is a gut-selective, non-lethal, small-molecule inhibitor of microbial choline trimethylamine-lyase (CutC/D). Developed by the Cleveland Clinic and licensed to Zehna Therapeutics, IMC acts as a mechanism-based, irreversible suicide substrate that selectively blocks the conversion of dietary choline to trimethylamine (TMA) by gut bacteria. This inhibition subsequently prevents the hepatic synthesis of trimethylamine N-oxide (TMAO), a pro-atherogenic and pro-fibrotic uremic toxin. Preclinical studies have demonstrated that IMC effectively reduces circulating TMAO levels, attenuates renal tubulointerstitial fibrosis, preserves kidney function, prevents diet-induced obesity, and reduces the risk of cardiovascular complications such as atrial fibrillation and atherosclerosis.

Other names

IMC